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OBJECTIVES: To evaluate the differences in statin usage among
patients with conﬁrmed CAD or related risk factors between
Europe & US to derive insights into practice behavior that may
impact disease burden. METHODS: Data from a large multi-
country cardiovascular research initiative involving primary-care
physicians (PCPs) and specialists to collect outpatient chart data
(for cardiovascular patients) was analyzed to evaluate the use of
statins (including high-doses: 80 mg atorvastatin/simvastatin,
20 mg rosuvastatin) among patients with CAD or CAD-
equivalent (myocardial Infarction, PCI/CABG/diabetes), periph-
eral vascular disease (PVD), cerebral ischemia (CI), Diabetes
(any-type) and other risk factors (CAD-RF: hypertension/
low-HDL/age/sex/smoking/family-history of CVD). Patient
conditions/risk-factors were not mutually exclusive. Analysis
included 2006 data from US and 5 major countries in Europe
(EU5, reported in aggregate). RESULTS: In total, 23,321
& 5,008 patient charts were abstracted by 2299 & 587
PCPs/specialists in EU5 & U.S respectively. Distribution of
patients was (condition: EU5, US)—CAD: 28.5%, 23.0%, CAD-
equivalent: 66.1%, 65.1%, diabetes: 46.5%, 52.8%, PVD:
6.6%, 7.4%, cerebral ischemia: 4.4%, 2.8%, CAD-RF <=: 5.6%,
8.7%, CAD-RF > 1: 28.4%, 26.1%. The CAD group had
the highest statin utilization rate (EU5:69.5%, US:63.2%),
followed by PVD (EU5:59.7%, US:56.2%), CI (EU5:57.4%,
US:51.1%), CAD-equivalent (EU5:54.8%, US:50.8%),
Diabetes (EU5:50.7%, US:49.5%), CAD-RF > 1 (EU5:28.7%,
US:30.1%), CAD-RF<= (EU5:24.5%, US:24.5%). Correspond-
ing utilization rates of high-dose statins were: CAD—
EU5:0.7%, US:9.5%, PVD—EU5:0.5%, US: 9.5%, CI—
EU5:0.8%, US:7.1%, CAD-equivalent—EU5:0.5%, US:6.1%,
Diabetes—EU5:0.4%, US:5.5%, CAD-RF > 1—EU5:0.5%,
US:2.8%, CAD-RF<=-EU5:0.6%, U.S:1.8%. CONCLUSION:
Both in EU5 & US, close to one-third of CAD-patients and >40%
of patients in CAD-equivalent/PVD/CI/Diabetes groups were not
on any statins. High-dose statin use was sparse in both EU5 &
the U.S with the utilization rates slightly higher in the U.S.
Further scrutiny is warranted to evaluate the drivers behind these
utilization patterns and their impact on health outcomes.
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OBJECTIVES: To evaluate LDL cholesterol goal attainment
among high risk CVD patients in Europe & US, and to assess the
percentage of patients meeting US NCEP/ATP-III guideline’s new
criteria of <70 mg/dl LDL for high risk patients. METHODS:
CVD patient charts from outpatient settings were abstracted by
primary-care physicians and specialists in US & Europe as part of
a large multi-country research initiative. CVD patients with LDL
cholesterol data from US and 5 major countries in Europe (EU5,
reported in aggregate) in 2006 were included in this analyses
and risk stratiﬁed into following 3 categories: High-risk (with
coronary artery disease, myocardial Infarction, PCI/CABG,
peripheral vascular disease, cerebral ischemia, diabetes (any-
type)), Medium-risk (with >1 risk factors) and Low-risk (with 0
or 1 risk factors). Risk factors included: hypertension/low-HDL/
age/sex/smoking/family-history of CVD. RESULTS: In total over
16,500 patients were evaluated (EU5 13,246 and US 3,597).
Distribution of patients for EU5 and US respectively
were—High-risk: 9617 and 2615, Medium-risk 3093 and 768,
and Low-risk: 536 and 214. Percentage of patients at different
levels of LDL (mg/dl) in EU5/US were—High risk <100: 31.0%/
49.0% 100-to-<130: 35.4%/34.1%, 130-to-<160: 23.4%/
11.3%, >=160: 10.1%/5.5%; Medium-risk in EU5/US <100:
17.0%/29.6%, 100-to-<130: 34.9%/47.8%, 130-to-<160:
32.0%/16.8%, >=160: 16.0%/5.9%, and among Low-risk
groups (EU5/US): <100: 15.5%/29.0%, 100-to-<130: 34.7%/
40.7%, 130-to-<160: 34.5%/25.7%, >=160: 15.3%/4.7%.
Evaluation of patients at LDL < 70 mg/dl within the High-risk
group per NCEP/ATP-III guideline recommendations revealed
that only 8.8% & 13.7% met the criteria in EU5 & US re-
spectively. CONCLUSION: Almost two-thirds (EU5) and one-
half (US) of High-risk CVD patients did not meet the
LDL < 100 mg/dL goal in 2006. Further, patients in EU5 appear
to considerably lag behind those in the US in every CVD risk level
(in LDL goal attainment), contributing to disproportionate
disease burden in respective market segments.
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OBJECTIVES: Dyslipidemia is the most common reason of
atherosclerosis which is associated with the high risk of myo-
cardial infarction, cerebrovascular diseases and other cardiovas-
cular complications. Cholesterol lowering therapy has been
shown to reduce cardiovascular mortality and morbidity.
National and international guidelines have deﬁned LDL-
cholesterol treatment initiation levels and aims for patients with
different levels of coronary heart disease risk according to the
number of coronary heart disease risk factors associated to dys-
lipidemia. It is crucial for health care system to analyze utili-
sation and costs of hypolipdemics. Adherence to the short and
long term treatment guidelines could lead to ﬁnancial saving in
health care systems. The aim of the study was to collect com-
parable and reliable data on the lipid lowering therapy in
Slovak republic during 1998–2005. METHODS: Data used for
analyses were obtained from the Slovak Institute for Drug
Control. Wholesalers are legally obliged provide the drug con-
sumption information to the institute. RESULTS: The obtained
data showed large increases hypolipidemics consumption from
1998 to 2005 (from 7.34 DID (DDD per 1000 inhabitants per
day) in 1998 to 39.12 DID in 2005). Consumption of statins
was signiﬁcant (from 1.96 DID in 1998 to 3.16 DID in 2005).
Consumption of ﬁbrates increased moderate (from 5.12 DID in
1998 to 8.72 DID in 2005). Lipid lowers generics coming into
the pharmaceutical market led to the price cut-downing (from
€0.95/DDD to €0.64 per DDD). CONCLUSION: Lipid lower-
ing generics drug coming into the Slovak pharmaceutical
market led to increased of lipid lowers consumption and to
price reduction of lipid lowers. Financial expenditures for
health insurance companiesx funds remained under control and
more patients could be treated for high cholesterol levels and
high risk of cardiovascular diseases in Slovak republic during
1998–2005.
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